Kornimate/medical-research-clean huggingface dataset:
sleep restriction and parental history of hypertension

Conditions: Hypertension

Summary: the purpose of this study is to research the effects of partial sleep deprivation (sleep restriction) in a group of individuals whose parents have high blood pressure compared to a group of individuals whose parents have normal blood pressure.


Eligibility criteria:
inclusion criteria * healthy adults aged 18-35 years * absence of any significant medical or psychiatric disease (as per the investigators' judgment) * nonsmoker * nonpregnant * history of normal sleep duration (reported average sleep duration between 7-9 hours/night and no habitual napping) * both biological parents with medical records from mayo clinic or rochester epidemiology project * ability to understand study procedures and to comply with them for the entire length of the study * ability to understand english and provide informed consent exclusion criteria * age \ 35 years * body mass index \<18.5 or ≥30 kg/m2 * pregnant or lactating * unable to determine history of hypertension in participant's biological parents or subject being adopted * use of tobacco, vaping, marijuana products or other drugs * excessive caffeine consumption (\>400 mg/day) * excessive alcohol consumption (\>7 drinks/week for women, \>14 drinks/week for men) * office systolic/diastolic blood pressure (sbp/dbp) ≥130/80 mmhg * daytime ambulatory sbp/dbp ≥130/80 mmhg * fasting glucose ≥126 mg/dl * glomerular filtration rate \<60 ml/min/bsa * history of significant medical or psychiatric disorders (as per the investigators' judgment) * regular use of prescription medications other than contraceptives * use of melatonin supplements or any other over-the-counter sleep aid * moderate-to-severe sleep disordered breathing (apnea/hypopnea index, ahi ≥15) or mild sleep disordered breathing (ahi 5-15) with daytime sleepiness (epworth sleepiness scale \>10) * moderate-to-severe insomnia (insomnia severity index \>14) * restless leg syndrome (as per the cambridge-hopkins questionnaire) * excessive daytime sleepiness (epworth sleepiness scale \>15) * extreme chronotype (morningness-eveningness questionnaire \>69 or \<31) * night shift work * habitual high levels of physical activity (\>3000 met×minutes/week)125 * ongoing participation in other research studies (as per the investigators' judgment) * any other medical, geographic, or social factor making study participation impractical * not english-speaking and/or inability to provide informed consent * exclusionary for blood draws: hemoglobin \<11.6 g/dl in women / \<13.2 g/dl in men; participants with measured hemoglobin levels below these thresholds will be allowed to continue participate in study tests and procedures not involving blood draws.
a safety and activity study of ns2 in subjects with allergic conjunctivitis

Conditions: Allergic Conjunctivitis; Seasonal Allergies

Summary: this is a randomized, parallel, single center, double masked, vehicle controlled study. the purpose of this study is to determine the activity and safety of ns2 in patients with grass, tree or ragweed-pollen induced seasonal allergic conjunctivitis . subjects will be randomized 1:1 to receive multiple doses of ns2 ophthalmic drops (0.5%) or ns2 ophthalmic drops vehicle (0.0%). free aldehydes are thought to be related to inflammatory conditions such as allergic conjunctivitis. ns2, a small molecule aldehyde trap, is being evaluated to determine whether it may decrease inflammation by lowering aldehyde levels.


Eligibility criteria:
inclusion criteria: * graded conjunctival redness in at least one region (nasal or temporal) in each eye at any one time point (not necessarily the same time point) post-capt (conjunctival allergen provocation test) of \>2 * graded ocular itching at any one time point * visual acuity of at least 20/50 in each eye * at least 2 year history of moderate to severe allergic conjunctivitis. * positive skin prick test to ragweed, grass and/or tree pollen within one year of screening visit (visit 1). * ability to avoid any topical or systemic ocular medications during the entire study period. exclusion criteria: * subjects must not have an ocular itching score \>0 or a conjunctival redness score \>1 prior to capt in either eye in any region (nasal or temporal) at visits 2-4. i * history of glaucoma, or intraocular pressure (iop) over 25mmhg at the screening visit, or a history of elevated iop within the past 1 year. * ocular surgery, including laser procedures, within the past 12 months of visit 1. * use of glaucoma medications, antibiotics, antivirals, or topical cyclosporine within 1 month of the screening visit. * history of dry eye syndrome, blepharitis, herpes simplex keratitis or herpes zoster keratitis. * history of uveitis in the past 3 years. * presence of any ocular infection or active ocular inflammation (e.g. follicular conjunctivitis, allergic conjunctivitis) within 14 days prior to start of study (visit 1). * history of moderate to severe asthma or allergy induced asthma to the allergen that will be used in capt. * use of oral corticosteroids within 30 days of screening and throughout the study period; use of intranasal or inhaled corticosteroids within 14 days of screening and throughout the study period. * use of antihistamines (ocular, nasal, topical or oral) within 7 days prior to screening (visit 1) and throughout the study period. non-medicated artificial tears are allowed up to 72 hours before screening (visit 1) and throughout the study period.

Keywords: allergic conjunctivitis seasonal allergies ragweed allergy grass allergy tree allergy ns2 aldeyra
effects of rehydration during physical exercise on acute kidney injury biomarkers

Conditions: Acute Kidney Injury

Summary: rehydration during and after physical exercise is essential to avoid acute kidney injury. soft drinks are commonly used during exercise. high intake of carbohydrates is leading to obesity and metabolic disorders. fructose intake is leading to uric acid abnormalities and kidney injury. 30 healthy soccer players will be studied. during four training sessions subjects will intake 500 ml 7% soft drinks containing glucose, fructose, saccharose or xylitol. changes in acute kidney injury markers, markers of kidney tubular function as well as changes in crp, glucose, cholesterol and uric acid levels will be studied..


Eligibility criteria:
inclusion criteria: * age above 18 years * well-trained soccer players * informed consent exclusion criteria: * chronic diseases, especially kidney problems * sigificant changes in urinalysis * creatinine level above normal values

Keywords: biomarker albuminuria uric acid
recombinant human thrombopoietin in combination with rituximab in immune thrombocytopenia (itp)

Conditions: Purpura; Idiopathic Thrombocytopenic Purpura

Summary: the purpose of this study is to determine whether recombinant human thrombopoietin (rh-tpo) in combination with rituximab are effective and safe in the management of steroid-resistant/relapsed immune thrombocytopenia (itp).

rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (day 1, 8, 15, 22). rh-tpo (tpiaotm, a product of sunshine pharmaceutical co ltd, china, approved by china state food and drug administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (day 1-14). platelet count (pc) was monitored every three or four days until day 22, followed by tests every week. platelet transfusion was administered to patients with active bleeding symptoms or to those whose pc\<10×10\^9/l. patients were followed for 3 months, and any adverse effects were recorded during the period of treatment and during the follow-up.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for immune thrombocytopenia. 2. untreated hospitalized patients, may be male or female, between the ages of 18 \~ 80 years. 3. to show a platelet count \<30×10\^9/l, and with bleeding manifestations. 4. willing and able to sign written informed consent. exclusion criteria: 1. received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit. 2. received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit. 3. received high-dose steroids or ivig in the 3 weeks prior to the start of the study. 4. current hiv infection or hepatitis b virus or hepatitis c virus infections. 5. severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 6. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period. 7. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test. 8. patients who are deemed unsuitable for the study by the investigator.

Keywords: purpura idiopathic thrombocytopenic purpura
gemcitabine plus carboplatin versus carboplatin monotherapy in patients with advanced ovarian cancer

Conditions: Ovarian Cancer

Summary: the primary objective of this study is to compare the time to progressive disease in patients treated with gemcitabine plus carboplatin versus carboplatin monotherapy. patients will have advanced epithelial ovarian cancer and have failed first-line platinum-containing therapy 6 months after treatment discontinuation.

carboplatin is commonly used for the treatment of ovarian cancer in first- and second-line therapy. the efficacy of gemcitabine in ovarian carcinoma was researched in various phase 2 studies.

Eligibility criteria:
inclusion criteria: * histologically proven ovarian cancer with evidence of recurrence or progression * failed first-line platinum containing therapy after 6 months of treatment discontinuation * documented lesion as evidenced by appropriate computerized tomography (ct), magnetic resonance imaging (mri) scan, chest x-ray, or ultrasound. * previous hormonal therapy or radiotherapy must be terminated at least 3 weeks before study drug administration * adequate bone marrow reserve: neutrophils ≥ 1.5 x 10\^9/l and platelets ≥ 100 x 10\^9/l exclusion criteria: * receiving concomitant cytotoxic or other antineoplastic treatment. hormone replacement therapy is allowed, as are steroid antiemetics * clinical evidence of central nervous system metastases * active infection * cannot adequately be followed up for the duration of the study * a second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) * use of any investigational agent in the 3 weeks prior to inclusion * serious concomitant systematic disorders incompatible with the study * received more than one previous chemotherapy regimen or had prior gemcitabine treatment * patients with tumor of borderline malignancy * patients with estimated gfr ≤ 50 ml/min

Keywords: ovarian cancer recurrence or progression gemcitabine plus carboplatin vs carboplatin
nexium dyspepsia/ast

Conditions: Gastrointestinal Disease; Signs and Symptoms, Digestive; Dyspepsia

Summary: the aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Eligibility criteria:
inclusion criteria: * at least 3 months of symptoms of pain or burning centered in the upper abdomen prior to enrollment. * both helicobacter pylori positive and negative patients eligible (helicobacter pylori is a bacterial infection of the stomach) exclusion criteria: * presence of clinical significant abnormal findings at the endoscopy (examination of esophagus and stomach) prior to enrollment. * patients with symptoms of other gastrointestinal diseases, such as gastroesophageal reflux disease (gerd), irritable bowel syndrome (ibs) or inflammatory bowel disease (ibd). * helicobacter pylori eradication treatment during the last 12 months prior to enrollment.
the prevalence survey of aldh gene family in patients with peripheral arterial occlusive disease or acute coronary syndrome

Conditions: Peripheral Artery Occlusive Disease; Acute Coronary Syndrome

Summary: aldehyde dehydrogenase 2 (aldh2) is an important enzyme protecting human from the accumulation of aldehyde, the main metabolites of alcohol. the deficiency of aldh2 gene results in flush and hang over post drinking and most importantly it has been found associated with the incidence of cancer and post myocardial infarction (mi) heart failure. in the previous studies, aldh2 decreased the ischemic territory post infarction and using a large scaled interaction of genetic variants and aldh2 as an instrument, the threats of alcohol consumption on asians' cardiovascular health was underscored. furthermore, in a meta-analysis reviewing 12 case-control studies also indicated an increase of 48% risks in patients with aldh2 deficiency. notably, the genetic deficiency is most prevalent in asians. in taiwan one of every two individuals may be the victim and the high prevalence is counted as the top of the world. however, a large scaled prospective study focusing on the prevalence of aldh2 deficiency in patients with peripheral artery occlusive disease (paod) or acute coronary syndrome （acs）remains lacking.


Eligibility criteria:
inclusion criteria: 1. age≧20 y/o 2. using ankle-brachial index (abi)\< 0.9, angiography, vascular duplex, cat scan or cardiologists'impression to confirm the diagnosis of paod 3. clinical presentation of claudication 4. diagnosis of acs exclusion criteria: * if the patient refuses to be included in this study

Keywords: peripheral artery occlusive disease or acute coronary syndrome
anxiety lowering and deprescribing through emotion regulation

Conditions: Benzodiazepine Dependence; Anxiety Disorders; Sleep Disturbance

Summary: the goal of this clinical trial is to test alder (anxiety lowering and deprescribing through emotion regulation), an online self-guided positive emotion intervention, in patients over the age of 65 who are candidates for benzodiazepine receptor agonist (bzra, commonly called benzos, or z-drugs) deprescribing. the main questions it aims to answer are: * is alder relevant to and satisfactory for older adult bzra users? * does alder help to increase positive emotions and decrease anxiety, trouble sleeping, and use of bzra medications? participants will complete the 5-week online self-guided alder intervention as well as two survey assessments, one before the intervention and one after.

alder (anxiety lowering and deprescribing through emotion regulation) is a pilot trial of an online positive emotion intervention for adults age 65 and over who are candidates for benzodiazepine receptor agonist (bzra) deprescribing. the alder intervention is 5 weeks long and involves weekly self-guided positive emotion skill lessons and daily skill practice exercises, both housed on the alder website. up to n=40 patients over the age of 65 will be recruited from northwestern medicine primary care clinics. to participate, patients must have (1) a bzra prescription from northwestern medicine primary care within the past year, (2) at least 1 nm primary care visit in the past year, and (3) take a bzra at least twice a week. participants will complete survey assessments via redcap before and after they go through the alder intervention. all study activities will take place online. feasibility, acceptability, and adoption of the alder program will be assessed using enrollment and retention rates, website user data, and measures of relevance and satisfaction in the post-intervention assessment. patient reported outcomes such as anxiety, sleep and positive affect will be measured both pre- and post-intervention and rate of bzra usage will be extracted from participant medical records.

Eligibility criteria:
inclusion criteria: * age 65 and over. * ≥1 nm internal medicine clinic visit within the past year. * bzra prescribed by nm primary care within the past year. * takes bzra at least twice a week. * daily access to internet-connected device. * ability to read and speak english. exclusion criteria: * dementia, seizure, or rem sleep disorder diagnosis. * in hospice care. * no daily internet access. * cannot speak and read english.

Keywords: benzodiazepine receptor agonists positive emotion sleep disturbance anxiety coping stress
weekly family food packages: food is medicine

Conditions: Food Insecurity; Overweight; Obesity; Cardiometabolic Syndrome

Summary: the specific aims and objectives of this proposal are to: 1. evaluate a food pantry's weekly food distribution impact on behavioral, social and health outcomes in families. 2. in a subset of families with a child aged 6-17 years, test a pilot intervention offering the following components, with a goal of improving family behavioral, social and health outcomes: 1. weekly family food packages from the revere food pantry 2. 6-monthly group sessions that include information on healthy behaviors, chronic disease management and teaching families how to prepare simple recipes based on the food they receive that week from the food pantry.


Eligibility criteria:
inclusion criteria: * referral to the food pantry additional inclusion criteria for group sessions: - family has a child aged 6-17 years exclusion criteria: - not able to speak english or spanish
nebulized magnesium sulfate and sildenafil for persistent pulmonary hypertension of newborn

Conditions: Persistent Pulmonary Hypertension of Newborn

Summary: the aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe persistent pulmonary hypertension on mechanical ventilation.

persistent pulmonary hypertension of newborn (pphn) is a serious condition that results from failure of the normal postnatal circulatory transition and is associated with significant mortality and morbidity. advanced medical treatment, such as inhaled nitric oxide (ino), high-frequency ventilation (hfv), and extracorporeal membrane oxygenation (ecmo) are commonly not available in developing countries. intravenous magnesium sulfate has been shown to alleviate pulmonary hypertension but is associated with systemic hypotension and is less effective compared with ino and sildenafil. nebulized magnesium sulfate has been reported to be more effective and safer compared with intravenous magnesium sulfate in treating neonates with pphn on mechanical ventilation. combined nebulized magnesium and sildenafil has been studied in a small trial on spontaneously breathing neonates with pphn but not on those connected to mechanical ventilation. the aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe pphn on mechanical ventilation. we hypothesize that neonates with severe pphn connected to mechanical ventilation could benefit from taking continuous nebulization of magnesium sulfate combined besides sildenafil.

Eligibility criteria:
inclusion criteria: * gestational age ≥ 36 weeks * birth weight between 2.5 and 4 kg. * post-natal age between 6 and 72 hours. * pphn confirmed by echocardiography * oxygenation index (oi) \> 30 on two occasions at least 15 minutes apart * connected to mechanical ventilation exclusion criteria: * failure to obtain informed consent * newborns to mothers who received magnesium sulfate within 48 hours before labor. * congenital heart diseases, other than patent ductus arteriosus and foramen ovale. * major congenital anomalies (including congenital diaphragmatic hernia and lung hypoplasia). * prior need for cardiopulmonary resuscitation. * mean arterial blood pressure (mabp) \< 35 mmhg despite therapy with volume infusions and vasoactive inotropes. * impaired kidney function. * prior administration of pulmonary vasodilators. * gastrointestinal intolerance or bleeding

Keywords: neonate persistent fetal circulation persistent pulmonary hypertension of the newborn pphn magnesium sulfate nebulizer hypoxia mechanical ventilation
sexually transmitted infections among african american women who have sex with women

Conditions: Sexually Transmitted Infections

Summary: the purpose of this study is to determine rates of sexually transmitted infections (stis) among african american women who have sex with women (aawsw). in addition, the study is interested in better understanding the types of risk behaviors that place aawsw at risk for stis. the investigators hypothesis is that aawsw experience high rates of stis, similar to heterosexual african american women. knowledge gained from this study will guide development of interventions to reduce women's risk for these types of infections and will improve how aawsw are screened for stis.

the objectives of this study are (1) to determine the prevalence of bacterial vaginosis, trichomoniasis, chlamydia, gonorrhea, mycoplasma genitalium, hiv, genital herpes, and syphilis and associated risk behaviors in a cohort of african american women who have sex with women (aawsw) in birmingham, alabama; (2) to compare exclusive aawsw (during the past 12 months) to african american women who have sex with women and men (aawswm) in terms of socio-demographic characteristics, sexual risk behavior characteristics, and sti prevalence; and(3) to perform an exploratory prospective study of an age-matched (± 2 years) sub-group of exclusive aawsw and aawswm over a 12 month time period to obtain data on differences in sti risk behaviors and sti incidence rates.

Eligibility criteria:
inclusion criteria: * female gender, self-identification as african american * age of 16 years or older, self report of sexual contact (oral, vaginal, or anal) with another female within the past 12 months * english speaking * the ability to give written informed consent. * for the sub-groups of women being followed prospectively, they have to have at least one active female sexual partner (aawsw group) or at least one active female and male sexual partner (aawswm group) at the time of enrollment into the study. exclusion criteria: * pregnant or nursing and the inability or unwillingness to give written informed consent.